Mutations within the EGFR signaling pathway: Influence on efficacy in FIRE-3-A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients

被引：1

作者：

Stintzing, Sebastian

Jung, Andreas

Rossius, Lisa

Modest, Dominik Paul

von Weikersthal, Ludwig Fischer

Decker, Thomas

Kiani, Alexander

Al-Batran, Salah-Eddin

Vehling-Kaiser, Ursula

Heintges, Tobias

Moehler, Markus

Scheithauer, Werner

Kirchner, Thomas

Heinemann, Volker

机构：

[1] Ludwig Maximilians Univ Munchen, Klinikum Grosshadern, Dept Hematol & Oncol, Munich, Germany

[2] Ludwig Maximilians Univ Munchen, Ctr Comprehens Canc, Munich, Germany

[3] Univ Munich, Inst Pathol, D-80539 Munich, Germany

[4] Univ Munich, Klinikum Grosshadern, Ctr Comprehens Canc, Dept Hematol & Oncol, D-80539 Munich, Germany

[5] Gesundheitszentrum St Marien GmbH, Dept Oncol, Amberg, Germany

[6] Onkonet Onkol Ravensburg, Ravensburg, Germany

[7] Klin Herzoghohe, Bayreuth, Germany

[8] UCT Univ Canc Ctr, Krankenhaus Nordwest, Inst Clin Canc Res IKF, Frankfurt, Germany

[9] Stadt Klinikum Neuss Lukaskrankenhaus GmbH, Dept Med 2, Neuss, Germany

[10] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Gastroenterol & Hepatol, D-55122 Mainz, Germany

[11] Med Univ Vienna, Vienna, Austria

[12] Univ Munich, Dept Pathol, Munich, Germany

来源：

关键词：

D O I：

10.1200/jco.2014.32.3_suppl.445

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

445

引用

页数：1